Brokers Set Expectations for Valneva SE’s FY2024 Earnings (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) – Investment analysts at HC Wainwright decreased their FY2024 earnings estimates for Valneva in a research note issued to investors on Friday, October 11th. HC Wainwright analyst E. White now forecasts that the company will earn $0.00 per share for the year, down from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.02 per share.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. The company had revenue of $40.97 million during the quarter, compared to the consensus estimate of $46.83 million.

Valneva Price Performance

Shares of VALN opened at $5.63 on Monday. Valneva has a fifty-two week low of $5.57 and a fifty-two week high of $14.49. The company has a market capitalization of $456.82 million, a price-to-earnings ratio of -10.83 and a beta of 2.17. The firm has a 50-day simple moving average of $6.77 and a 200-day simple moving average of $7.44. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.15 and a current ratio of 2.63.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. General American Investors Co. Inc. boosted its position in Valneva SE (NASDAQ:VALN) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 354,361 shares of the company’s stock after purchasing an additional 9,361 shares during the period. General American Investors Co. Inc. owned about 0.51% of Valneva worth $2,831,000 as of its most recent filing with the Securities & Exchange Commission. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.